Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Marc Evans, Anja Schweizer & James E Foley. (2016) Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus. Vascular Health and Risk Management 12, pages 337-340.
Read now
Read now
Matthias Blüher, Anja Schweizer, Giovanni Bader & James E Foley. (2014) Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. Vascular Health and Risk Management 10, pages 661-664.
Read now
Read now
Antoni Sicras-Mainar & Ruth Navarro-Artieda. (2014) Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly. Drug Design, Development and Therapy 8, pages 811-818.
Read now
Read now
Valentina Lukashevich, Anja Schweizer, James E Foley, Sheila Dickinson, Per-Henrik Groop & Wolfgang Kothny. (2013) Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vascular Health and Risk Management 9, pages 21-28.
Read now
Read now
Articles from other publishers (11)
Fatma Haddad, Ghadeer Dokmak, Maryam Bader & Rafik Karaman. (2023) A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. Life 13:4, pages 1012.
Crossref
Crossref
Sanjay Chatterjee & Saurav Chatterjee. (2015) Vildagliptin With Metformin Once-Daily Regimen-Insights From a Single-Center Analysis. American Journal of Therapeutics 22:3, pages 195-198.
Crossref
Crossref
Bo Ahrén, James Edward Foley, Sylvie Dejager, Mouna Akacha, Qing Shao, Guenter Heimann, Markus Dworak & Anja Schweizer. (2014) Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?. Diabetes Therapy 5:2, pages 459-469.
Crossref
Crossref
George Grunberger. (2014) Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. European Journal of Clinical Pharmacology 70:11, pages 1277-1289.
Crossref
Crossref
Dominique Simon, Bruno Detournay, Evelyne Eschwege, Stephane Bouée, Jacques Bringer, Claude Attali & Sylvie Dejager. (2014) Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study. Diabetes Therapy 5:1, pages 207-224.
Crossref
Crossref
Gillian M. Keating. (2014) Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 74:5, pages 587-610.
Crossref
Crossref
Michael Brines, Ann N. Dunne, Monique van Velzen, Paolo L. Proto, Claes-Goran Ostenson, Rita I. Kirk, Ioannis N. Petropoulos, Saad Javed, Rayaz A. Malik, Anthony Cerami & Albert Dahan. (2014) ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Molecular Medicine 20:1, pages 658-666.
Crossref
Crossref
Hiroyuki Ito, Mizuo Mifune, Eriko Matsuyama, Masahide Furusho, Takashi Omoto, Masahiro Shinozaki, Shinya Nishio, Shinichi Antoku, Mariko Abe, Michiko Togane, Shoji Koga & Tsutomu Sanaka. (2013) Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis. Diabetes Therapy 4:2, pages 321-329.
Crossref
Crossref
Iu Sh Khalimov. (2013) DPP-4 inhibitors and hypoglycemia in the patients with type 2 diabetes mellitus. Problems of Endocrinology 59:5, pages 72-80.
Crossref
Crossref
George Grunberger. (2013) Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物：第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物). Journal of Diabetes 5:3, pages 241-253.
Crossref
Crossref
Jun Sung MoonKyu Chang Won. (2013) The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes. Diabetes & Metabolism Journal 37:1, pages 36.
Crossref
Crossref